Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705631 | 0.73 | ADRB2 (0.38) | — | |
| SCHEMBL20089307 | 0.73 | — | — | |
| SCHEMBL29623571 | 0.72 | PLAU (0.30) | — | |
| SCHEMBL20089299 | 0.72 | PLAU (0.30) | — | |
| SCHEMBL4706996 | 0.70 | ALDH1A1 (0.36) | — | |
| SCHEMBL974627 | 0.70 | BACE1 (0.37) | — | |
| SCHEMBL4949794 | 0.67 | — | — | |
| SCHEMBL12499425 | 0.67 | — | — | |
| SCHEMBL20095054 | 0.66 | MAPT (0.34) | — | |
| SCHEMBL6639146 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| CN-109843887-B | Nalidinone derivatives and their use in the treatment of cardiac arrhythmias | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210284635-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2021-09-16 | — | — | US | disclosed |
| US-10844055-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20190263803-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10266531-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2019-04-23 | — | — | US | disclosed |
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284635-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | DGAT1 3564/4885 |
| US-10266531-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | DGAT1 3668/4885 |
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | DGAT1 3564/4885 |
| US-10844055-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | DGAT1 3668/4885 |
| US-20190263803-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | DGAT1 3564/4885 |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | DGAT1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.